Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial
Published Online: 2021-05-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Anjun Cao•Aruna Mehra•Aryan Hamed•Barrett H Childs•Eduardo Yañez•Fangfang Lv•Florian Hiemeyer•Guray Saydam•Igor Bondarenko•Jie Jin•Jifeng Feng•Katya Sapunarova•Klaus Geissler•Krimo Bouabdallah•Lidia Mongay Soler•Marcelo Capra•Matthew J Matasar•Mihaela Lazaroiu•Ming-Chung Wang•Muhit Özcan•Pier Luigi Zinzani•Qingyuan Zhang•Rinat Galiulin•Ross Baker•Tongyu Lin•Toshiki Uchida•Wei Li•Wojciech Jurczak•Yuankai Shi•Árpád Szomor
